Precipio achieved $5.7 million in revenue in Q2 2025, driven by growth in both product and pathology divisions. The company posted net income of $100,000 and continued improving operational performance, reflected in an 87% YoY improvement in adjusted EBITDA.

Precipio delivered a 43% YoY revenue increase in Q1 2025, driven by gains in both its Products and Pathology Services divisions. Gross margins improved substantially, and adjusted EBITDA showed significant progress toward profitability, reflecting better cost control and operational efficiency.

Precipio, Inc. reported positive Adjusted EBITDA of $0.4 million and a positive cash flow increase of $0.3 million in Q4 2024, indicating a significant step towards financial independence and profitability.